Acute Respiratory Distress Syndrome (ARDS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

 

Acute respiratory distress syndrome (ARDS) is non-cardiogenic pulmonary edema that manifests as rapidly progressive dyspnea, tachypnea, and hypoxemia leading to respiratory failure reason is roughly one-half of intensive care units (ICUs). ARDS progresses through several phases after a direct pulmonary or indirect extrapulmonary insult. In the exudative phase, which may last seven to 10 days, alveolar macrophages secrete mediators that lead to the accumulation of inflammatory cells in the lung. In surfaces, pro-inflammatory mediators, and chemokines, this accumulation is released, leading to pathologic vascular permeability, gaps in the alveolar epithelial barrier, and necrosis of types I and II alveolar cells. Intravascular coagulation in the alveolar capillaries leads to microthrombi. Most cases of ARDS in adults are associated with pneumonia with or without sepsis (60%) or nonpulmonary sepsis (16%).

• The incidence of ARDS varies from 26 to 68 cases per 100,000 population in the USA.

Thelansis’s “Acute Respiratory Distress Syndrome (ARDS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Acute Respiratory Distress Syndrome (ARDS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Acute Respiratory Distress Syndrome (ARDS) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Acute Respiratory Distress Syndrome (ARDS) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Acute Respiratory Distress Syndrome (ARDS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032